hotspot -WSS

hotspot

author：explore 2025-10-08 20:25:03 - browse：69326

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

focus

WSS

Testing for cancer recurrence creates a new limbo for patients

Readout Newsletter: What happened with Sarepta's Duchenne data

Physician subsidies by hospitals soar in wake of No Surprises Act

Hilary expected to bring catastrophic, life

Ukraine taking heavy casualties 10 weeks into its counteroffensive

Majority of Americans think Trump's Ga. election interference case is serious: POLL

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

As demand for Covid shots wanes, Moderna seeks its next success

Chimpanzees, like humans and whales, get menopause: Study

Anesthesiologist group: stop taking Ozempic before surgery

As Maui death toll rises, number of missing remains unclear

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Living with Hashimoto's and celiac disease, and med school, too

Psychedelics group wrestles with new pharma identity

Liz Cheney makes 1st public comment since Trump's election interference indictments

Sports medicine is finally prioritizing gender equality

Senate panel to vote on hospitals, PBMs, prisoner care

leisure time

Cassava reveals details — and problems — with Alzheimer's study

The FDA weighs the risks of candy

New definition of a human embryo proposed amid rapid advances

Cassava reveals details — and problems — with Alzheimer's study

Testing for cancer recurrence creates a new limbo for patients

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

entertainment

leisure time

focus

explore